blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3535390

EP3535390 - E-WE THROMBIN ANALOG AND FIBRINOLYTIC COMBINATION [Right-click to bookmark this link]
StatusThe application has been withdrawn
Status updated on  12.11.2021
Database last updated on 02.11.2024
FormerRequest for examination was made
Status updated on  09.08.2019
FormerThe international publication has been made
Status updated on  18.05.2018
Most recent event   Tooltip12.11.2021Withdrawal of applicationpublished on 15.12.2021  [2021/50]
Applicant(s)For all designated states
Aronora, Inc.
4640 SW Macadam Avenue
Suite 200A
Portland, OR 97239 / US
[2019/44]
Former [2019/37]For all designated states
Tucker, Erik L.
1151 S.W. Park Avenue 1307
Portland, OR 97201 / US
For all designated states
Markway, Brandon D.
5905 N. Boston Avenue
Portland, OR 97217 / US
For all designated states
Wallisch, Michael N.
3315 S.W. Marigold Street
Portland, OR 97219 / US
For all designated states
Verbout, Norah G.
15802 N.E. 25th Avenue
Vancouver, WA 98686 / US
Inventor(s)01 / see applicant
...
 [2019/37]
Representative(s)Murgitroyd & Company
165-169 Scotland Street
Glasgow G5 8PL / GB
[N/P]
Former [2019/37]Hanna Moore + Curley
Garryard House
25/26 Earlsfort Terrace
Dublin 2, D02 PX51 / IE
Application number, filing date17868883.402.11.2017
[2019/37]
WO2017US59702
Priority number, dateUS201662416631P02.11.2016         Original published format: US 201662416631 P
[2019/37]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2018089248
Date:17.05.2018
Language:EN
[2018/20]
Type: A2 Application without search report 
No.:EP3535390
Date:11.09.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 17.05.2018 takes the place of the publication of the European patent application.
[2019/37]
Search report(s)International search report - published on:US14.06.2018
(Supplementary) European search report - dispatched on:EP28.10.2020
ClassificationIPC:A61K38/48, A61K38/49, A61K38/16, A61P7/02, A61P9/10
[2020/48]
CPC:
A61K38/4833 (EP,US); A61K38/166 (EP); A61K38/49 (EP,US);
A61P7/02 (EP,US); A61P9/10 (EP,US)
C-Set:
A61K38/166, A61K2300/00 (EP);
A61K38/4833, A61K2300/00 (EP);
A61K38/49, A61K2300/00 (EP)
Former IPC [2019/37]C12N9/64, A61K38/48
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/37]
TitleGerman:E-WE-THROMBIN-ANALOG UND FIBRINOLYTISCHE KOMBINATION[2019/37]
English:E-WE THROMBIN ANALOG AND FIBRINOLYTIC COMBINATION[2019/37]
French:COMBINAISON D'ANALOGUE DE THROMBINE E-WE ET D'UN FIBRINOLYTIQUE[2019/37]
Entry into regional phase16.05.2019National basic fee paid 
16.05.2019Search fee paid 
16.05.2019Designation fee(s) paid 
16.05.2019Examination fee paid 
Examination procedure02.09.2018Request for preliminary examination filed
International Preliminary Examining Authority: US
16.05.2019Examination requested  [2019/37]
25.05.2021Amendment by applicant (claims and/or description)
09.11.2021Application withdrawn by applicant  [2021/50]
Fees paidRenewal fee
30.01.2020Renewal fee patent year 03
13.11.2020Renewal fee patent year 04
Penalty fee
Additional fee for renewal fee
30.11.201903   M06   Fee paid on   28.05.2020
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XY]US6110721  (GIBBS CRAIG S [US], et al) [X] 1,3,7-9,12,16 * column 27, lines 29-34; claims 7,26 * [Y] 1-16;
 [Y]WO03006042  (THROMBOTECH LTD [IL], et al) [Y] 1-16 * the whole document *;
 [Y]EP1964556  (SHIONOGI & CO [JP]) [Y] 1-16 * the whole document *;
 [Y]US2013259853  (SAGER THOMAS NIKOLAJ [DK], et al) [Y] 1-16 * the whole document *;
 [A]  - PAUL R EISENBERG, "Importance of Modulating Balance of Procoagulant and Fibrinolytic Activit to Success of Antithrombotic Therapy", CIRCULATION, (19911201), vol. 84, no. 6, pages 2601 - 2603, XP055740927 [A] 1-16 * the whole document *
 [T]  - KLEGERMAN MELVIN E, "Translational initiatives in thrombolytic therapy", FRONTIERS OF MEDICINE, HIGHER EDUCATION PRESS, HEIDELBERG, vol. 11, no. 1, doi:10.1007/S11684-017-0497-8, ISSN 2095-0217, (20170302), pages 1 - 19, (20170302), XP036506838 [T] * the whole document *

DOI:   http://dx.doi.org/10.1007/s11684-017-0497-8
International search[A]US6174855  (HANSSON HANS-ARNE [SE]) [A] 1-39 * entire document *;
 [A]US7223583  (GRUBER ANDRAS [US], et al) [A] 1-39 * entire document *;
 [Y]US2012164129  (DI CERA ENRICO [US], et al) [Y] 1-39 * entire document *;
 [Y]US2015099298  (WILMEN ANDREAS [DE], et al) [Y] 1-39 * entire document *;
 [A]WO2015112547  (UNIV OREGON HEALTH & SCIENCE [US], et al) [A] 1-39* entire document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.